Navigation Links
Cough in Medical Technology

PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

... observed. Baseline data showed that CF patients cough a remarkable 643 times per day on average, with a ... day. In comparison, healthy individuals generally cough fewer than 16 times per day, according to the ... PTC124 experienced a mean [28%] decrease in cough frequency by the end of three months of therapy ...

PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis

... - Findings Show Cystic Fibrosis Patients cough More Than 600 Times Per Day ... outcome measure in cystic fibrosis (CF). cough is one of the most prominent and ... the American Thoracic Society, patients with CF cough a remarkable 324 to 1,569 times per day, with an ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and ... lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and ... lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and ... lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash ...

PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients

... 320 to 1,330 coughs per day, compared to healthy individuals who typically cough fewer than 16 times per day, according to the European Respiratory Journal (Hsu 1994). Patients in this study experienced a mean decrease in cough frequency of almost 200 coughs per day by the end of the study (p<0.01). ...

TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet

... Side effects associated with ACE inhibitors include intolerable cough and rare, but potentially life threatening, angioedema.(4-6) "The ... events. N Eng J Med 2008; 358(15):1547-59. (4) Israili ZH, Hall WD. cough and angioedema associated with angiotensin-converting enzyme inhibitor ...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

... lymphopenia (24% vs 17%), anorexia (23% vs 10%), asthenia (21% vs 18%), cough (21% vs 13%), insomnia (20% vs 13%), edema peripheral (20% vs 10%), rash ... paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and ...

PA Department of Health Reports Rise in Flu Activity; Reminds Public of Need for Flu Shot

... and warm water. -- Cover your mouth and nose with a tissue when you cough or sneeze. If you don't have a tissue, cough or sneeze into your upper sleeve, not your hands. -- Clean your hands ...

Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection

... (ACCP) guidelines recommend a chest X-ray for patients with cough and risk factors for lung cancer or metastatic cancer.(6) -- ... Radiology Society of North America. (6) Kvale, P.A. (2006). Chronic cough due to lung tumors: ACCP evidence- based clinical practice ...

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

... the introduction of two new COLD-EEZE brand extensions, Organix(TM) cough and Sore Throat Drops and COLD-EEZE Immune Support Complex-10 (ISC-10) ... to support their health during the upcoming Cold and Flu Season. Organix cough and Sore Throat Drops is a proprietary product manufactured in the ...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

... , surgery and the surgical subspecialties . Montefiore is a national leader in the research and treatment of diabetes, headaches , obesity, cough and sleep disorders , geriatrics and geriatric psychiatry , neurology and neurosurgery , adolescent and family medicine , HIV/AIDS and ...

International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit

... has been mined in Michigan and Minnesota. The patient has experienced increasing pain on her right side for the past 31 years, a persistent cough and wheezing. As the pain increased so did her medication. Using the new imaging approach, Dr. Harbut was able to show the progression of the ...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

... neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent). Please visit www.dacogen.com for full ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... an infection or if you have or develop any signs of an infection such as: fever, sweat, or chills muscle aches cough shortness of breath blood in phlegm weight loss warm, red, or painful skin or sores on your body diarrhea or ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... an infection or if you have or develop any signs of an infection such as: fever, sweat, or chills muscle aches cough shortness of breath blood in phlegm weight loss warm, red, or painful skin or sores on your body diarrhea or ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... The most common adverse reactions irrespective of causality (incidence greater than or equal to 30%) were stomatitis, infections, asthenia, fatigue, cough and diarrhea. The most common grade 3/4 adverse reactions irrespective of causality (incidence greater than or equal to 3%) were infections, dyspnea, ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... The most common adverse reactions irrespective of causality (incidence greater than or equal to 30%) were stomatitis, infections, asthenia, fatigue, cough and diarrhea. The most common grade 3/4 adverse reactions irrespective of causality (incidence greater than or equal to 3%) were infections, dyspnea, ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is ...

Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference

... area, known as the meningitis belt, is prone to meningitis epidemics because of its six-month dry season when winds whip up dust, causing people to cough and sneeze. F. Marc LaForce, MD, director of the Meningitis Vaccine Project, a partnership between WHO and PATH, will discuss the roll-out of ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... in pregnant women. The most common adverse reactions (incidence greater than or equal to 30%) were stomatitis, infections, asthenia, fatigue, cough and diarrhea. The most common grade 3/4 adverse reactions (incidence greater than or equal to 3%) were infections, dyspnea, fatigue, stomatitis, ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

... neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 percent), petechiae (39 percent), constipation (35 percent), and diarrhea (34 percent). Please visit www.Dacogen.com for full ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia ...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

... doses compared with formoterol, budesonide and placebo.(1) -- Both SYMBICORT doses significantly (P<.028) improved the sum of Breathlessness, cough and Sputum Scores (BCSS), sleep score, awakening-free nights, and rescue medication use versus placebo.(1) -- Both doses of SYMBICORT were ...

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

... a result of adverse events (three related to lung infections and two related to cough). The most common adverse events attributed to treatment were cough in 9% of the subjects and sore throat in 5%. Other reported adverse events related to treatment were infrequent, mild in severity and in most ...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.dacogen.com for full prescribing information. About ...

New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

... and its analogs (e.g., headache, nausea, dizziness, flushing) and those commonly associated with the inhalation route of administration (e.g., cough and throat irritation). These side effects were mostly mild or moderate in severity and were not dose-limiting in the majority of patients treated ...

Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone

... nighttime awakenings, and total symptom scores all improved significantly with the Perforomist(TM)/TIO treatment compared with TIO/placebo (p<0.05). cough scores did not differ between groups. Albuterol use declined in the Perforomist(TM)/TIO group from 2.4 to1.3 puffs/day and increased in the ...

Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD

... events were headache (4.1% of patients), dry mouth (2.8% of patients), exacerbation of chronic obstructive airways disease (1.7% of patients) and cough (1.7% of patients). Based on these results, aclidinium 200 mcg administered once every 24 hours was selected as the dose for investigation in the two ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.mgipharma.com or http://www.dacogen.com for full ...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

... the most common adverse reactions in > or = 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs <1% placebo), somnolence (3% vs <1% placebo) and epistaxis (2% vs <1% placebo). Full prescribing information for XYZAL(R) is available at ...

New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer

... 8%), diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19%), dermatology-other (27%, 6%), and stomatitis (25%, 10%). About ImClone Systems ImClone Systems Incorporated is a fully integrated ...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

... have had tuberculosis (TB), a positive skin test for TB, recent close contact with someone who has had TB or develop any of the symptoms of TB (a dry cough that doesn't go away, weight loss, fever, night sweats) should call their doctor right away. Before starting treatment with ORENCIA, a doctor may ...

Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate

... have had tuberculosis (TB), a positive skin test for TB, recent close contact with someone who has had TB or develop any of the symptoms of TB (a dry cough that doesn't go away, weight loss, fever, night sweats) should call their doctor right away. Before starting treatment with ORENCIA, a doctor may ...

CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year

... occurrence (<5 percent) of treatment discontinuation due to adverse events. The most commonly reported adverse events were headache, nasopharyngitis, cough and abdominal pain. Reported serious adverse reactions were infections (including tuberculosis) and malignancies (including lymphoma), consistent ...

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer

... diarrhea (39%, 20%), vomiting (37%, 29%), infection without neutropenia (35%, 17%), headache (33%, 11%), fever (30%, 18%), insomnia (30%, 15%), cough (29%, 19%), dermatology-other (27%, 6%), and stomatitis (25%, 10%). About ImClone Systems ImClone Systems Incorporated is a fully integrated ...

Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Don't Vaccinate

... switches, faucets or plastic toys. Use a disinfectant designed to kill cold and flu viruses. * Do the Elbow Cough: Teach kids to cough into elbows, not hands where they're more likely to spread bacteria and viruses through touch. "The best treat we can give our ...

ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review

... have had tuberculosis (TB), a positive skin test for TB, recent close contact with someone who has had TB or develop any of the symptoms of TB (a dry cough that doesn't go away, weight loss, fever, night sweats) should call their doctor right away. Before starting treatment with ORENCIA, a doctor may ...
Other Contents
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... can swim up to 400 kilometres in search of a ... change. , Clownfish spend their entire adult lives under the ... wander the open ocean, says study co-author, Dr Hugo Harrison ... (Coral CoE) at James Cook University. , "In the past ... given a rare glimpse into how far they can swim, ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Nemo's epic journey to find a new home 2Mellon Foundation awards grant for major project in the humanities and sciences 2
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
Other TagsOther Tags